Challenges in the Management of Pediatric IBD: Expanding Treatment Options

New Data from IMAgINE 1 Trial Provide Insights on Biologic Use in Pediatric Crohn’s Disease

Interferon-Free Therapies Head for Approval in Hepatitis C on the Basis of Phase 3 Data

Bile Acid Malabsorption Proves to Be Surprisingly Frequent Source of Readily Reversible Chronic Diarrhea

Beyond TNF Inhibitors for IBD: New Safety and Efficacy Data Move Adhesion Factor Inhibitors Forward

Optimization of PPI Therapy in GERD: Need for Acid Control Over Each 24-hour Period

Adhesion Factor Inhibitors Fundamentally Shift Risk-Benefit of Biologics in IBD

Suboptimal Adherence to Canadian GERD Guidelines: Opportunity for Improved Symptom Control and Patient Care

Phase 3 Study Validates New Biologic With Gut-Specific Directed Activity

National Survey Reveals Majority of PPI Users Achieve Inadequate Relief

Patients Believe Stress is an Important Factor in Inflammatory Bowel Disease

Improving PPI Therapy: Current Obstacles and Opportunities